Vaccine Exposure in First 23 Months Has No Adverse Impact
WEDNESDAY, March 7, 2018 -- The estimated cumulative vaccine antigen exposure through age 23 months does not differ significantly for children with versus those without hospital visits for infectious diseases not targeted by vaccines from age 24 to 47 months, according to a study published in the March 6 issue of the Journal of the American Medical Association.
Jason M. Glanz, Ph.D., from Kaiser Permanente Colorado in Denver, and colleagues conducted a nested case-control study in children aged 24 through 47 months in six U.S. health care organizations. Cases were identified by International Classification of Diseases codes for infectious diseases in the emergency department and inpatient medical settings; cases of non-vaccine-targeted infection were matched by age, sex, health care organization site, and chronic disease status to controls (193 cases and 751 controls).
The researchers found that the estimated mean cumulative vaccine antigen exposure was 240.6 for cases and 242.9 for controls through the first 23 months. For estimated cumulative antigen exposure, the between-group difference was −2.3 (95 percent confidence interval, −10.1 to 5.4; P = 0.55). The matched odds ratio for estimated cumulative antigen exposure through 23 months was not significant among children with versus those without non-vaccine-targeted infections from 24 through 47 months of age (matched odds ratio, 0.94; 95 percent confidence interval, 0.84 to 1.07).
"This study did not reveal any beneficial or detrimental associations with estimated cumulative vaccine antigen exposure in young children with non-vaccine-targeted infections," the authors write.
One author disclosed financial ties to the pharmaceutical industry.
© 2019 HealthDay. All rights reserved.
Posted: March 2018